Ospemifene Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 60 mg
Reference Brands: Osphena (USA/EU)
Category:
Women's Health
Ospemifene is available in Tablets
and strengths such as 60 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ospemifene is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ospemifene can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ospemifene, marketed under the brand names Osphena and Senshio, is an oral selective estrogen receptor modulator (SERM) designed for the treatment of dyspareunia, or pain during sexual intercourse, commonly experienced by postmenopausal women. By selectively acting on estrogen receptors in the vaginal epithelium, ospemifene helps restore the thickness and elasticity of the vaginal walls, alleviating discomfort and improving sexual function.
Dyspareunia in postmenopausal women is often caused by vulvovaginal atrophy, a condition resulting from decreased estrogen levels that leads to thinning, drying, and inflammation of vaginal tissues. Ospemifene provides estrogen-like effects specifically in the vaginal tissue while minimizing systemic estrogen exposure, offering a targeted, non-hormonal approach for long-term management of vaginal atrophy and associated sexual pain. Taken orally once daily, ospemifene improves vaginal health, reduces pain during intercourse, and enhances quality of life for women experiencing postmenopausal symptoms.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing